Huadong Medicine (HD Medicine) (000963.SZ)

Executive Summary

Huadong Medicine (HD Medicine), a leading Chinese pharmaceutical company listed on the Shenzhen Stock Exchange (000963.SZ) with a market capitalization of approximately $8.9 billion, is well-positioned in China's rapidly evolving pharmaceutical landscape. Founded in 1993 and headquartered in Hangzhou, the company has built a robust generics business while pivoting toward innovative medicines across diabetes, oncology, and autoimmune disease. With ten commercial products and over 115 publications, HD Medicine demonstrates strong R&D capabilities and a commitment to addressing high unmet medical needs. Its transition from a traditional generic manufacturer to a biotech innovator is underpinned by a focused pipeline of novel therapies, including GLP-1 receptor agonists and immuno-oncology candidates, which are expected to drive future growth. The company's near-term prospects hinge on advancing its key pipeline assets. HD-199, a dual GLP-1/GIP receptor agonist for type 2 diabetes, is in late-stage development and could be a major growth catalyst if approved. Additionally, HD Medicine is exploring oncology with a PD-L1 inhibitor and other immuno-oncology targets. With a strong balance sheet, established commercial infrastructure, and strategic partnerships (e.g., with Zealand Pharma for HD-199), the company is poised to capture significant market share in China's expanding diabetes and oncology markets. While regulatory and competitive risks persist, the valuation remains attractive given the pipeline potential and solid base business.

Upcoming Catalysts (preview)

• Q4 2026NDA submission for HD-199 (GLP-1/GIP dual agonist) in type 2 diabetes70% success
• H1 2027Phase 2 data readout for HD-? (PD-L1 inhibitor) in solid tumors50% success
• Q2 2026Out-licensing or partnership deal for HD-199 ex-China rights40% success